Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2019.04.015
Abstract: BACKGROUND Tumour mutational burden (TMB) estimated from whole exome sequencing or comprehensive gene panels has previously been established as predictive factor of response to immune checkpoint inhibitors (ICIs). Its predictive value for the efficacy of concurrent… read more here.
Keywords: tmb; tumour mutational; cancer; gene ... See more keywords
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of cancer"
DOI: 10.1016/j.ejca.2020.02.038
Abstract: Treatment with immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand (PD-L1) can generate durable responses in various cancer types, but only in a subset of patients. The use of predictive… read more here.
Keywords: biomarker immunotherapy; tumour mutational; biomarker; burden biomarker ... See more keywords
Benchmarking bioinformatics approaches for tumour mutational burden evaluation from a large cancer panel against whole-exome sequencing
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pathology"
DOI: 10.1136/jcp-2022-208385
Abstract: Tumour mutational burden (TMB) is used to predict response to immunotherapies. Although several groups have proposed calculation methods for TMB, a clear consensus has not yet emerged. In this study, we explored TMB calculation approaches… read more here.
Keywords: cancer panel; tumour mutational; whole exome; panel ... See more keywords
Heterogeneity of tumour mutational burden in metastatic NSCLC demonstrated by endobronchial ultrasound sampling
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1150349
Abstract: Introduction Tumour mutational burden (TMB) is an important emerging biomarker for immune checkpoint inhibitors (ICI). The stability of TMB values across distinct EBUS tumour regions is not well defined in advanced lung cancer patients. Methods… read more here.
Keywords: heterogeneity; tumour mutational; primary metastatic; cohort ... See more keywords